We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Malignant neoplasms of ill-defined, secondary and unspecified sites
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Drug resistance to cancer therapy is a severe impediment to treatment and a contributor to the 166,000 cancer deaths that occur in the UK every year.
The objective of this observational study is to understand the common mechanisms behind treatment resistance across different cancers and in doing so, potentially identifying novel drug targets and inform the design of novel therapeutic interventions. Where possible, we will also monitor changes to tumours during the course of treatment to identify how these treatment targets might change through disease progression.
We propose undertaking a detailed analyses of tumours at a genomic, epigenomic, transcriptomic and phenotypic level, and in a longitudinal manner where possible. In parallel, information on treatment response and other clinical features will also be collected so that we can correlate the laboratory data to clinical information. We will collect samples from individuals undergoing a tissue biopsy as part of their routine clinical care.
Upon study completion we will have a deeper and more granular understanding of how drug resistant tumours and their microenvironments evade our current cancer treatments, and how we can design novel therapeutics to exploit these newly elucidated mechanisms.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
1. Individuals without capacity to consent to trial participation 2. Individuals who have not given written informed consent
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST and funded by CANCER RESEARCH UK; Medical Research Council (MRC); .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 58094
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
